Riboflavin plays an important role in myelin formation, and its deficiency is implicated as a risk factor for multiple sclerosis. Here, we systematically reviewed the literature concerning the health benefits of riboflavin on MS. The literature recorded within four main databases, including relevant clinical trials, experimental, and case-control studies from 1976 to 2017 were considered. Both human and animal studies were included for review, with no restrictions on age, gender, or ethnicity. Experimental studies demonstrated that riboflavin deficiency triggers neurologic abnormalities related to peripheral neuropathies such as demyelinating neuropathy. Moreover, randomized controlled trials (RCT) and case-control studies in which MS patients received riboflavin supplementation or had higher dietary riboflavin intake showed improvements in neurological motor disability. Riboflavin is a cofactor of xanthine oxidase and its deficiency exacerbates low uric acid caused by high copper levels, leading to myelin degeneration. The vitamin additionally plays a significant role in the normal functioning of glutathione reductase (GR) as an antioxidant enzyme, and conditions of riboflavin deficiency lead to oxidative damage. Riboflavin promotes the gene and protein levels of brain-derived neurotrophic factor (BDNF) in the CNS of an animal model of MS, suggesting that BDNF mediates the beneficial effect of riboflavin on neurological motor disability. Research to date generally supports the role of riboflavin in MS outcomes. However, further observational and interventional studies on human populations are warranted to validate the effects of riboflavin.
Introduction
Multiple sclerosis (MS) is a demyelinating inflammatory disease of the central nervous system (CNS) (1) . The Atlas of MS 2013 has documented an increase in the incidence of MS worldwide from 2.1 million in 2008 to 2.3 million in 2013 (2) . On the National MS Society website, more than 900 clinical trials on MS sponsored by the National Institutes of Health have been registered since 2000, including over 300 ongoing or planned studies investigating the effects of different treatments. At present, only eight FDA-approved agents for treatment of relapsing forms of MS are available (3), highlighting the urgent need for new and effective therapeutic approaches for MS (4) . Riboflavin (7, 8-dimethyl-10-ribityl-isoalloxa zine), also known as vitamin B2, is a water soluble vitamin present in a variety of foods, a micronutrient with a key function in maintaining human health (5) . The most important biologically active forms of riboflavin, flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN), participate in a range of redox reactions, some of which are absolutely essential for aerobic cell function (6) . Riboflavin is also critical for proper functioning of the nervous, endocrine, cardiovascular, and immune systems. For human subjects and animals that are unable to synthesize riboflavin, the main sources are food and activities of intestinal microflora (5) .
Riboflavin deficiency is endemic in many regions worldwide, (7) particularly developing countries, (8) and certain population groups have low dietary intakes (9, 10) . Riboflavin deficiency has been implicated as a risk factor in a number of diseases, (10, 11) including MS (12) . In addition, the vitamin clearly plays an important role in myelin formation (13) (14) (15) (16) (17) (18) . However, few reports to date have focused on the effects of inadequate riboflavin intake and /or supplementation on demyelinating diseases. A PubMed search with the keywords "demyelination" and "riboflavin" yields limited citations of studies over the last decade.
Considering the growing interest in the putative role of riboflavin in protecting against demyelinating disease (12, 14, 15, (18) (19) (20) , evaluation of its metabolic roles, and the public health relevance of low intake of this vitamin on MS disease is warranted. Here, we have provided an updated overview of literature focusing on the correlation between MS and riboflavin, considering recent publications.
Materials and Methods

Search Strategy
The cited publications were generally identified by searching the National Library of Medicine PubMed database (pubmed.gov), MEDLINE, Science Direct, Scopus, and Google Scholar using the terms "demyelination", "multiple sclerosis", "encephalomyelitis, autoimmune, expe-rimental", "riboflavin", and "riboflavin deficiency", in accordance with the Medical Subject Heading (MeSH). Studies on both animals and humans were included, with no restrictions on age, gender, or ethnicity. A manual search of the references cited in the identified studies was additionally conducted.
Firstly, a search strategy was developed using the MeSH terms in MEDLINE (OvidSP) as well as the relevant keywords. All the individual relevant words, phrases, and abbreviations (e.g., "riboflavin", "multiple sclerosis", "MS", and "demyelination") or a combina -tion were used. All similar phrases (e.g., amyolateral sclerosis, amyotrophic lateral sclerosis, and systemic sclerosis) were excluded. The following broader MeSH terms were added to the search: "riboflavin deficiency", "Dietary Supplements", "encephalomye -litis, autoimmune, experimental", and "Peripheral Nervous System Diseases" (Figure 1 ).
The search for the relevant published papers was accomplished in two phases.
The first phase focused on original studies with clinical trials and experimental and observational designs. The original search was conducted in September 2016 and updated at the end of February 2017. This lag time allowed us to incorporate the most recent publications, and thereby, the maximum number of studies. The second phase focused on screening of original studies for eligibility. The relevant full-text manuscripts with high quality were screened at the abstract/title levels. At this level, papers with at least two main keywords (e.g., "riboflavin", "multiple sclerosis", "MS", and "demyelination" or a combination) were included and allocated to experimental and human studies 
Inclusion and exclusion criteria
Clinical trials and experimental and case-control studies examining dietary riboflavin, riboflavin supplementations, and deficiencies associated with the clinical, histological, and biochemical nature of the disease involving human subjects and an animal model of MS and demyelination polyneuropathies were included. Articles were excluded based on the following grounds: no specific assessment of demyelinating conditions and other aspects of MS, such as inflammation and axonal loss, e.g., those exam-ining autoimmune and inflammatory diseases, such as human and animal models of brain injuries and amyotrophic lateral sclerosis. No search restrictions were imposed in terms of animal species, age, gender, race, geographical residence, or source of patient participants (e.g., hospital, outpatients, community, registry, or health administrative data).
The outcomes of interest were changes in laboratory and histological biomarkers as well as clinical evaluations, including expanded disability status scale (EDSS) test for assessment of neurological motor disabilities ( Figure 1 ). EDSS is a 20-point scale (ranging from 0 = normal to 10 = death due to MS, marked by a 0.5 score increase) and currently, the most widely used method to evaluate motor disability in MS (21) . This measurement is an expansion of the disability status scale (DSS) that applies the same range without 0.5 increments (22) .
Finally, the comprehensive topic of the association between riboflavin status and onset or progression of MS was reviewed and a brief overview provided. Table 1 summarizes RCTs and case-control studies in which MS patients received riboflavin supplementation or were exposed to high dietary riboflavin intake (12, 23, 24) . One RCT demonstrated a significant reduction in EDSS in response to riboflavin supplementation, along with improvement of cognitive function (23) . In a double-blind RCT in which MS patients in treatment and control groups received either riboflavin supplementation (10 mg/day) or placebo daily for six months, application of riboflavin did not improve disability status. This effect was not related to serum homocysteine levels (12) . A negative linear trend between higher intake of riboflavin and risk of MS was observed in a casecontrol study (24) . In several experiments (14-19, 25, 26) (Table 2) , animals maintained on riboflavindeficient diets showed signs of neuropathy and pathologic changes in the sciatic nerve in a timedependent manner (26) . Similar alterations appeared in cervical and lumbar spinal nerves, characterized by hypertrophic Schwann cells, tomacula (redundant myelin swellings), demyelination/remyelination (14), fibroblastic onion bulb-like structures in sciatic and brachial nerves (19) , and acquired primary demyelinating tomaculous neuropathy in sciatic and brachial nerves (16) . Pathological evaluation of peripheral nerves revealed demyelinating neuropathy with the formation of paranodal tomacula occurred early in the course of demyelination along with increased frequency of myelinated fibers, indicative of demyelination in avian riboflavin deficiency model of demyelination (25) . Peripheral nerve lesions comprising swelling and discoloration of all the peripheral nerve trunks were observed. Moreover, microscopic lesions, including moderate to severe swelling, fragmentation and demyelination of myelin sheaths, atrophy, and loss of axons (17), Schwann cell swelling, perivascular leukocytic infiltration, segmental demyelination, (15, 18) accompanied by accumulation of osmiophilic debris in Schwann cell cytoplasm, and axon degeneration (15, 18) were common.
Results
Riboflavin and MS risk
The collective findings support the utility of riboflavin as a clinically effective treatment option for MS patients and animal models. However, further RCTs are required to provide solid evidence of the benefits of riboflavin supplementation.
Riboflavin as an immunomodulatory agent
Injection of riboflavin reduces mortality of mice with septic shock (27) , enhances resistance to bacterial infection (28) , and affects neutrophil migration, but does not alter acquired immune responsiveness (29) . On the other hand, riboflavin deficiency results in lower neutrophil phagoc-ytosis (30), increased prostaglandin biosy-nthesis in rat kidney (31) , and impaired hemato-poiesis through hindering iron absorption (7). Iron acts as an oxidation agent (via the Fenton reaction) and riboflavin decreases oxidative stress by reducing iron absorption. As discussed in a previous review by our group, riboflavin itself is considered an antioxidant. Other possible mechanisms by which riboflavin protects the body against oxidative stress may be attributed to the glutathione redox cycle and the conversion of reduced riboflavin to the oxidized form (32) . Accordingly, we hypothesized that riboflavin could act as an anti-inflammatory agent via decreasing oxidative stress. Removal of riboflavin from the culture medium resulted in lower cell viability and accelerated cell death, resulting in a strikingly high fraction of late apoptotic cells with compromised membranes in a murine monocyte/macrophage cell line; the monocyte/ macrophage is sensitive to riboflavin deficiency in culture medium (5) . As professional phagocytes, macrophages play a crucial role in pathogen elimination but this ability appears to be significantly limited in macrophages with riboflavin deficiency (5). Macrophages play a dual role in MS pathology. These cells exert neuroprotective and growth promotory effects on the one hand but contribute to tissue damage via production of inflammatory mediators on the other (33) . The various effector functions of macrophages in the formation of lesions include signaling events that move these cells into the white matter of CNS and trigger pathways that facilitate the destruction of myelin. For instance, macrophages have been identified as producers of a number of proinflammatory cytokines, chemo-kines, and toxic molecules known to promote demyelination, the major responders to CNS chemokines, and the key cells involved in phago-cytosis/degradation of the myelin sheath. Interes-tingly, activated transcription factors, such as nuclear factor kappa B (NF-κB), signal transd-ucer, activator of transcription 1 (STAT1), and STAT6, in both leukocytes and CNS plaques of MS patients, lead to enhanced expression of these inflammatory effectors in macrophages (34) .
One RCT demonstrated favorable immunological changes in sera of MS patients administered a pharmaceutical form of riboflavin. In this study, Table 1 . Summary of human studies on the effects of riboflavin on multiple sclerosis 
Eighteen adult male rats were distributed into three equal groups. Each group was maintained on a specific diet: Group 1, complete diet (control); Group 2, riboflavindeficient diet; and Group 3, riboflavin-deficient diet plus galactoflavin, 2 g/kg of diet.
Sciatic nerve fibers demyelinated in animals maintained on riboflavin-deficient diets in a time-dependent manner. Cellular organelles of both myelinated and nonmyelinated nerve fibers remained intact and presumably functional.
PBS, phosphate buffer saline; EAE, experimental autoimmune encephalomyelitis; INFβ-1a, Interferon beta-1a; BDNF, brain-derived neurotrophic factor; IL-6, Interleukin-6; IL-17A, Interleukin-17A decreased levels of antibodies to the basic myelin protein were detected in MS patients treated with cytoflavin including riboflavin as a component, compared to the group that did not receive the drug. This decrease was associated with significant reduction of EDSS and improvement of cognitive function (23) . Moreover, our group showed that riboflavin at 10 mg/kg of body weight reduces motor disability accompanied by concomitant increased expression of IL-6 as a nouropointin immune factor and BDNF as a neurotrophic factor in the whole brain and spinal cord of experimental autoimmune encephalomyelitis (EAE) models of MS (35) . IL-6 stimulates proliferation of microglia in culture and potentially promotes survival through inducing BDNF (35, 36) . The results collectively demonstrate that riboflavin affects the immune system, and consequently exerts antinociceptive, anti-inflammatory (5), antioxidant (32) , and neuropro-tective (35, 37) effects.
Riboflavin, genetics, and MS
Riboflavin deficiency causes protein and DNA damage accompanied by cell cycle arrest, increased cell stress, and apoptosis. Furthermore, mutations in the SLC52A2 or SLC52A3 as genes encoding riboflavin transporters that convey riboflavin into neurons and other cells are often associated with chronic, severe, inflammatory demyelinating, and sensory-motor polyneuropathy (20, 38) . Nevertheless, treatment with riboflavin can terminate disease progression in most patients with riboflavin transporter disorders (20) .
Differential riboflavin status also strongly affects the expression of numerous genes (5).
The relative mRNA levels of antimicrobial peptides (liver-specific antimicrobial peptide 2 and hepcidin), anti-inflammatory cytokines (interleukin 10 and transforming growth factor β1), tight junction proteins (occludin, zonula occludens 1, claudin-c, and claudin-3), signalling molecules (inhibitor of κBα, target of rapamycin, and NF-E2-related factor 2), and antioxidant enzymes and agents (copper, zinc superoxide dismutase, and GR) are significantly decreased in gills of fish fed a riboflavin-deficient diet. Conversely, mRNA levels of proinflammatory cytokines (tumor necrosis factor α, interleukin 8, interferon γ2, and interleukin 1β), signaling molecules (NF-κB p65, IκB kinase β, IκB kinase γ, Kelch-like-ECH-associated protein 1β, and myosin light chain kinase) and tight junction protein, claudin-12, are markedly increased in gills of fish fed a riboflavindeficient diet. Moreover, relative mRNA expression of regulatory cytokines (IL-6) is significantly increased in EAE mice supplemented with riboflavin (35) . In conclusion, riboflavin acts as an antioxidant and potentially regulates cytokines, other antioxidant agents, gill tight junction proteins, and related signaling molecules at the transcriptional level (39) .
Discussion
Animal models of riboflavin deficiency display neurologic abnormalities related to peripheral neuropathy, such as demyelinating neuropathy characterized by Schwann cell hypertrophy and segmental demyelination, (14, 16, 19, 25) , and riboflavin supplementation is shown to improve neurological motor disabilities, such as central neuropathy, in animal models of MS (37) .
The precise mechanism by which riboflavin deficiency results in disruption of myelin lamellae is yet to be resolved. In addition to its role as an obligatory co-factor in numerous NADH dehydrogenation reactions, riboflavin acts at the first dehydrogenation step during fatty acid oxidation. In livers of weanling rats fed a riboflavin-deficient diet, mitochondrial fatty acid oxidation is suppressed, and conversely, restored after riboflavin supplementation (40) . Additionally, within the livers of riboflavindeficient rats, dehydrogenation of fatty acids is reduced, and consequently, linoleic, linolenic, and arachidonic acid contents in serum and liver decrease. The issue of whether or not the phenom-enon of nerve fiber demyelination is related to altered fatty acid metabolism remains uncertain. Biochemical evaluation of myelinated nerve fibers under experimental conditions of riboflavin deficiency confirmed that demyelination is the result of specific alterations in the synthesis, degradation, or composition of membrane constituents (26) .
Riboflavin is a coenzyme for xanthine oxidase, and its deficiency exacerbates low uric acid caused by high copper levels, leading to myelin degeneration (6) . Moreover, riboflavin deficiency leads to oxidative damage, which may be attributable to decreased catalase, copper/zinc superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione-S-transferase, and glutathione reductase (GR) activities and reduced glutathione content (39) . Riboflavin plays a critical role in the normal functioning of GR, an antioxidant enzyme required for conversion of oxidized glutathione to reduced glutathione (GSH). The latter is an important intracellular antioxidant that protects against reactive oxygen species (ROS) damage (10). As discussed in an earlier review, it is possible that riboflavin deficiency affects the antioxidant properties of glutathione, leading to impaired antioxidant potential of cells (32) . Deactivation of peroxides, such as hydroperoxide, is one of the most important antioxidant activities of glutathione, mediated through the action of GPx (41) . GPx transfers a hydrogen ion from reduced glutathione to lipid peroxide and produces oxidized glutathione and alcohol (42) . Accordingly, riboflavin deficiency is expected to enhance lipid peroxidation (32) . However, an earlier study disclosed no significant differences in serum levels of total antioxidant status (TAS) and dietary intake of antioxidants between MS patients and healthy controls; all subjects had low antioxidant status (43) .
Moreover, riboflavin deficiency interferes with electron transport along the respiratory chain (44) . Therefore, riboflavin-deficient cells deal with decreased energy production and are unable to maintain the intact cell membrane of early apoptotic cells. Consequently, these cells go through the early apoptosis stage rapidly to yield a higher level of secondary necrosis (5) .
Riboflavin additionally enhances the gene and protein levels of BDNF in the whole brain and spinal cord as well as IL-6 gene expression in brains of EAE mice, suggesting that IL-6 and BDNF contribute to the observed beneficial effects of riboflavin on neurological motor disability, therefore presenting targets for strategic therapies (35) . BDNF, an important regulator of neuronal maturation and protection, is expressed in and around MS lesions (45) . Immune factors regulate the BDNF levels and affect the survival of neuronal cells in vitro (45) . In this context, IL-6 may exert a proliferative effect on astrocytes in vitro (46, 47) synergistically with other factors (48) . Moreover, in vitro assays have shown that both virus-infected microglia and astrocytes secrete IL-6, which, in turn, triggers secretion of the neurotrophin nerve growth factor (NGF) by astrocytes (49) . In addition, microglia proliferate upon stimulation by IL-6 in culture and IL-6 possibly promotes survival through inducing BDNF (36) . In vivo, NGF in dorsal root ganglia (DRG) is not upregulated in riboflavin-deficient mice with nerve injury (36) . Thus, in many respects, IL-6 behaves in a neurotrophin-like fashion (50) . Moreover, riboflavin plays a critical role as a coenzyme for succinate dehydrogenase activity in complex II of the mitochondrial respiratory chain generating intracellular adenosine triphosphate (ATP) (51) . Since responses of CNS to circulating neurotrophic factors depend on the availability of intracellular ATP, riboflavin may enhance mitochondrial survival and bio-energy, leading to increased responsiveness to BDNF followed by enhanced myelin production in MS (Figure 2) (52) . Furthermore, riboflavin is found to have a crucial role in the production of substrates used for the electron transport chain (ETC). Accordingly, any defect in riboflavin transport would disrupt ETC and consequently lead to neurodegeneration. The schematic mechanism of riboflavin deficiency leading to mitochondrial oxidative stress-mediated neurodegeneration is summarized in Figure 3 (53) .
These findings strongly suggest that riboflavin acts as a neuroprotective nutrient, particularly against cytokines, ROS, and nitric oxide (NO), which contribute to damaging myelin sheath and neurons that lead to neurological motor disability and development of MS. 
Conclusion
Riboflavin may be considered a probable complementary agent to reduce the deleterious effects of neurological disability in MS and animal models. The mechanism by which riboflavin protects the body against demyelination possibly involves neurotrophins, especially BDNF, a crucial agent for neuronal maturation and protection. Since the majority of research in this area to date is limited to experimental studies, further interventional studies on human populations are required to establish the effects of riboflavin.
